On February 9, 2021 Convert Pharmaceuticals, a Belgian biotech company developing anti-cancer therapeutics, reported that it has obtained very promising pre-clinical results with CP-506 drug, a new and improved Hypoxia Activated Prodrug (Press release, Convert Pharmaceuticals, FEB 9, 2021, View Source [SID1234574773]). The company is finalising its Clinical Trial Application to obtain regulatory approval for the launch of its tumor agnostic Phase I Clinical Trial in 2021. This will be a first in human dose escalation study to determine the safety, pharmacokinetics, pharmacodynamics and phase 2 recommended dose. At the same time, we will check for the first indication of antitumor effect in humans.
CP-506 will be tested in both monotherapy, with patient selection based on validated biomarkers, as well as in combination with standard treatments such as immune checkpoint inhibitors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

We expect that by 2024 we will have completed the study with results that prompt us to continue the clinical development of CP-506 as the first antitumor drug from the HAP class.